Literature DB >> 30905674

Structures of the PKA RIα Holoenzyme with the FLHCC Driver J-PKAcα or Wild-Type PKAcα.

Baohua Cao1, Tsan-Wen Lu2, Juliana A Martinez Fiesco1, Michael Tomasini3, Lixin Fan4, Sanford M Simon3, Susan S Taylor5, Ping Zhang6.   

Abstract

Fibrolamellar hepatocellular carcinoma (FLHCC) is driven by J-PKAcα, a kinase fusion chimera of the J domain of DnaJB1 with PKAcα, the catalytic subunit of protein kinase A (PKA). Here we report the crystal structures of the chimeric fusion RIα2:J-PKAcα2 holoenzyme formed by J-PKAcα and the PKA regulatory (R) subunit RIα, and the wild-type (WT) RIα2:PKAcα2 holoenzyme. The chimeric and WT RIα holoenzymes have quaternary structures different from the previously solved WT RIβ and RIIβ holoenzymes. The WT RIα holoenzyme showed the same configuration as the chimeric RIα2:J-PKAcα2 holoenzyme and a distinct second conformation. The J domains are positioned away from the symmetrical interface between the two RIα:J-PKAcα heterodimers in the chimeric fusion holoenzyme and are highly dynamic. The structural and dynamic features of these holoenzymes enhance our understanding of the fusion chimera protein J-PKAcα that drives FLHCC as well as the isoform specificity of PKA. Published by Elsevier Ltd.

Entities:  

Keywords:  PKA holoenzyme; fibrolamellar hepatocellular carcinoma; kinase fusion; protein kinase PKA; structure

Mesh:

Substances:

Year:  2019        PMID: 30905674      PMCID: PMC6506387          DOI: 10.1016/j.str.2019.03.001

Source DB:  PubMed          Journal:  Structure        ISSN: 0969-2126            Impact factor:   5.006


  53 in total

Review 1.  The essential role of RI alpha in the maintenance of regulated PKA activity.

Authors:  Paul S Amieux; G Stanley McKnight
Journal:  Ann N Y Acad Sci       Date:  2002-06       Impact factor: 5.691

2.  An Isoform-Specific Myristylation Switch Targets Type II PKA Holoenzymes to Membranes.

Authors:  Ping Zhang; Feng Ye; Adam C Bastidas; Alexandr P Kornev; Jian Wu; Mark H Ginsberg; Susan S Taylor
Journal:  Structure       Date:  2015-08-13       Impact factor: 5.006

3.  Compensatory regulation of RIalpha protein levels in protein kinase A mutant mice.

Authors:  P S Amieux; D E Cummings; K Motamed; E P Brandon; L A Wailes; K Le; R L Idzerda; G S McKnight
Journal:  J Biol Chem       Date:  1997-02-14       Impact factor: 5.157

4.  Fibrolamellar carcinoma in the Carney complex: PRKAR1A loss instead of the classic DNAJB1-PRKACA fusion.

Authors:  Rondell P Graham; Carolin Lackner; Luigi Terracciano; Yessica González-Cantú; Joseph J Maleszewski; Patricia T Greipp; Sanford M Simon; Michael S Torbenson
Journal:  Hepatology       Date:  2018-05-11       Impact factor: 17.425

5.  Electrostatic Interactions as Mediators in the Allosteric Activation of Protein Kinase A RIα.

Authors:  Emília P Barros; Robert D Malmstrom; Kimya Nourbakhsh; Jason C Del Rio; Alexandr P Kornev; Susan S Taylor; Rommie E Amaro
Journal:  Biochemistry       Date:  2017-03-06       Impact factor: 3.162

6.  Fibrolamellar hepatocellular carcinoma occurring 5 years after hepatocellular adenoma in a 14-year-old girl: a case report with comparative genomic hybridization analysis.

Authors:  Luigi Maria Terracciano; Luigi Tornillo; Pierino Avoledo; Dietrich Von Schweinitz; Thomas Kühne; Elisabeth Bruder
Journal:  Arch Pathol Lab Med       Date:  2004-02       Impact factor: 5.534

Review 7.  A systematic review: treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma.

Authors:  Michael N Mavros; Skye C Mayo; Omar Hyder; Timothy M Pawlik
Journal:  J Am Coll Surg       Date:  2012-09-13       Impact factor: 6.113

8.  In vitro functional studies of naturally occurring pathogenic PRKAR1A mutations that are not subject to nonsense mRNA decay.

Authors:  Elizabeth L Greene; Anelia D Horvath; Maria Nesterova; Christoforos Giatzakis; Ioannis Bossis; Constantine A Stratakis
Journal:  Hum Mutat       Date:  2008-05       Impact factor: 4.878

9.  Model of fibrolamellar hepatocellular carcinomas reveals striking enrichment in cancer stem cells.

Authors:  Tsunekazu Oikawa; Eliane Wauthier; Timothy A Dinh; Sara R Selitsky; Andrea Reyna-Neyra; Guido Carpino; Ronald Levine; Vincenzo Cardinale; David Klimstra; Eugenio Gaudio; Domenico Alvaro; Nancy Carrasco; Praveen Sethupathy; Lola M Reid
Journal:  Nat Commun       Date:  2015-10-06       Impact factor: 14.919

Review 10.  Fibrolamellar Hepatocellular Carcinoma: Mechanistic Distinction From Adult Hepatocellular Carcinoma.

Authors:  Kevin M Riggle; Rigney Turnham; John D Scott; Raymond S Yeung; Kimberly J Riehle
Journal:  Pediatr Blood Cancer       Date:  2016-03-14       Impact factor: 3.167

View more
  8 in total

1.  Two PKA RIα holoenzyme states define ATP as an isoform-specific orthosteric inhibitor that competes with the allosteric activator, cAMP.

Authors:  Tsan-Wen Lu; Jian Wu; Phillip C Aoto; Jui-Hung Weng; Lalima G Ahuja; Nicholas Sun; Cecilia Y Cheng; Ping Zhang; Susan S Taylor
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-30       Impact factor: 11.205

Review 2.  A framework for fibrolamellar carcinoma research and clinical trials.

Authors:  Timothy A Dinh; Alan F Utria; Kevin C Barry; Rosanna Ma; Ghassan K Abou-Alfa; John D Gordan; Elizabeth M Jaffee; John D Scott; Jessica Zucman-Rossi; Allison F O'Neill; Mark E Furth; Praveen Sethupathy
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-02-21       Impact factor: 73.082

Review 3.  Liquid-liquid phase separation drives cellular function and dysfunction in cancer.

Authors:  Sohum Mehta; Jin Zhang
Journal:  Nat Rev Cancer       Date:  2022-02-11       Impact factor: 69.800

4.  Phase Separation of a PKA Regulatory Subunit Controls cAMP Compartmentation and Oncogenic Signaling.

Authors:  Jason Z Zhang; Tsan-Wen Lu; Lucas M Stolerman; Brian Tenner; Jessica R Yang; Jin-Fan Zhang; Martin Falcke; Padmini Rangamani; Susan S Taylor; Sohum Mehta; Jin Zhang
Journal:  Cell       Date:  2020-08-25       Impact factor: 41.582

Review 5.  Liquid-liquid phase separation: a principal organizer of the cell's biochemical activity architecture.

Authors:  Jason Z Zhang; Sohum Mehta; Jin Zhang
Journal:  Trends Pharmacol Sci       Date:  2021-08-06       Impact factor: 14.819

6.  An acquired scaffolding function of the DNAJ-PKAc fusion contributes to oncogenic signaling in fibrolamellar carcinoma.

Authors:  Rigney E Turnham; F Donelson Smith; Heidi L Kenerson; Mitchell H Omar; Martin Golkowski; Irvin Garcia; Renay Bauer; Ho-Tak Lau; Kevin M Sullivan; Lorene K Langeberg; Shao-En Ong; Kimberly J Riehle; Raymond S Yeung; John D Scott
Journal:  Elife       Date:  2019-05-07       Impact factor: 8.140

7.  Structural analyses of the PKA RIIβ holoenzyme containing the oncogenic DnaJB1-PKAc fusion protein reveal protomer asymmetry and fusion-induced allosteric perturbations in fibrolamellar hepatocellular carcinoma.

Authors:  Tsan-Wen Lu; Phillip C Aoto; Jui-Hung Weng; Cole Nielsen; Jennifer N Cash; James Hall; Ping Zhang; Sanford M Simon; Michael A Cianfrocco; Susan S Taylor
Journal:  PLoS Biol       Date:  2020-12-28       Impact factor: 8.029

8.  Defective internal allosteric network imparts dysfunctional ATP/substrate-binding cooperativity in oncogenic chimera of protein kinase A.

Authors:  Cristina Olivieri; Caitlin Walker; Adak Karamafrooz; Yingjie Wang; V S Manu; Fernando Porcelli; Donald K Blumenthal; David D Thomas; David A Bernlohr; Sanford M Simon; Susan S Taylor; Gianluigi Veglia
Journal:  Commun Biol       Date:  2021-03-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.